An observational study in Hereditary Hemorrhagic Telangiectasia, sponsored by University Hospital, Essen. Recruiting at 1 site in Germany. Open to participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2024-12-06.
Sponsored by University Hospital, Essen · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 10 studies in Telangiectasia, Hereditary Hemorrhagic with a site in Germany — 4 open to participants now, 6 under way, 1 of them phase 3. Telangiectasia, Hereditary Hemorrhagic · Germany.
Among the 10 studies in Telangiectasia, Hereditary Hemorrhagic with a site in Germany, this one is the only one that started in 2020, is one of 6 observational ones, and was the 6th registered.
106 studies on the registry are indexed under Telangiectasia, Hereditary Hemorrhagic; 24 are open to participants now.
Browse Telangiectasia, Hereditary Hemorrhagic studies →4 of the 10 studies in Telangiectasia, Hereditary Hemorrhagic with a site in Germany are open now. Recruiting first, the newest first:
Vaderis Therapeutics AG · Sites in Germany, United States, Belgium and 6 more countries
Ages 18+
University Hospital, Essen · Sites in Germany
Ages 18+
University Hospital, Essen · Sites in Germany
Ages 18+
A study can be open while its sites in Germany have not opened yet or have stopped. Only those recruiting at a site in Germany →
Of the 17 Telangiectasia, Hereditary Hemorrhagic studies recruiting now, 14 (82%) set no upper age limit and 2 (12%) stop at 75 or younger; 6 take children under 18; 3 take healthy volunteers.
This study: 18 Years and older · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
10 studies; the count open now beside each. This study's row is marked.
First in 2002; this study’s year is marked. 1 started in 2020.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 100 is below the median of 207 across 41 observational studies indexed under Telangiectasia, Hereditary Hemorrhagic.
Median enrollment 56 across the 4 interventional studies, 187 across the 6 observational. Of the 3 that completed or were terminated, 0 (0%) have results posted.
This tab as a report to print or save as PDF → With an account.
2 of 10 have an industry lead sponsor. The 4 most frequent:
University Hospital, Essen is the lead sponsor of 118 studies on the registry; 35 are open to participants now.
University Hospital, Essen has 8 studies filed under Telangiectasia, Hereditary Hemorrhagic — fewer than ten, so there is no comparison to draw.
None of the studies under way reaches primary completion within a year.
Among the 10 studies in Telangiectasia, Hereditary Hemorrhagic with a site in Germany, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
Patients with hereditary hemorrhagic telangiectasia (HHT) suffer from an inherited disorder leading to systemic vascular malformations. Mutations in several genes of the transforming growth factor (TGF)-β superfamily pathway influence angiogenesis in patients with HHT. The genetic loss of ALK1 or ENG alone are not sufficient to induce AVMs; environmental insults that could trigger angiogenesis (e.g. wounding) are also needed. In this study it will be analyzed if hypoxic induced factors could have an influence on the disease HHT.
Hereditary hemorrhagic telangiectasia (HHT) is characterized by systemic vascular malformations leading to recurrent bleedings and shunt formation especially in the liver, lungs and the brain. The underlying pathogenic HHT mechanism remains unclear. The wide variability in age of onset and severity of symptoms amongst patients, even within the same family, suggests several factors contribute to the complexity of this disease. Mutations in several genes of the transforming growth factor (TGF)-β superfamily pathway influence angiogenesis in patients with HHT. The genetic loss of ALK1 or ENG alone are not sufficient to induce AVMs; environmental insults that could trigger angiogenesis (e.g. wounding) are also needed. In this study it will be analyzed if hypoxic induced factors could have an influence on the disease HHT.
Patients with diagnosed hereditary hemorrhagic telangiectasie (HHT)
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
patients with HHT
Other: hypoxic induced factors
persons age- and sex matched who do not suffer from HHT nor their first or second degree relatives
Other: hypoxic induced factors
hypoxic induced factors analyzed in blood sample
Differences in hypoxic induced factors
Differences in hypoxic induced factors analyzed in blood samples from patients with HHT and healthy controls
Time frame: 12 months
Correlation of level of hypoxic induced factors and disease severity
Correlation of level of hypoxic induced factors in patients' blood sample and their disease severity
Time frame: 12 months
Plan to share: No
Started Aug 2020 (actual). Primary completion is estimated for Dec 2025, 64 months after the start.
Of 23 observational studies under Telangiectasia, Hereditary Hemorrhagic, half reached primary completion within 56 months of starting (the median), counting those still running; a quarter within 36 and three quarters within 184. This study's planned 64 months is above that.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Telangiectasia, Hereditary Hemorrhagic →